Array ( [0] => Applebot/0.1 [1] => facebookexternalhit/1.1 [2] => LinkedInBot/1.0 [3] => meta-externalagent/1.1 [4] => Amazonbot/0.1 [5] => BLEXBot/1.0 [6] => DotBot/1.2 [7] => Qwantbot/1.0_1997801 [8] => AhrefsBot/7.0 [9] => DataForSeoBot/1.0 [10] => MatchorySearch/1.3 [11] => WRTNBot/1.0 [12] => Sogou web spider/4.0 [13] => MojeekBot/0.11 [14] => Yeti/1.1 [15] => SeznamBot/4.0 [16] => SemrushBot-SI/0.97 [17] => MistralAI-User/1.0 [18] => Qwantbot/1.0 [19] => coccocbot-web/1.0 [20] => coccocbot-image/1.0 [21] => PlagAwareBot/3.2 [22] => Barkrowler/0.9 [23] => AwarioSmartBot/1.0 [24] => PetalBot [25] => archive.org_bot [26] => Iframely/1.3.1 [27] => LogRocket-AssetCacher [28] => Slackbot 1.0 [29] => node-fetch/1.0 [30] => MJ12bot/v1.4.8 [31] => MJ12bot/v2.0.0 [32] => Timpibot/0.9 [33] => AwarioBot/1.0 [34] => MJ12bot/v2.0.1 [35] => Qwantbot/1.0_2850318 [36] => SiteAuditBot/0.97 [37] => Scrapy/2.11.2 [38] => CCBot/2.0 [39] => MJ12bot/v2.0.2 [40] => Scrapy/2.13.3 [41] => WordPress/6.8.3 [42] => MJ12bot/v2.0.4 [43] => SemrushBot/7~bl [44] => Qwairy-Bot/1.0 [45] => Embedly/0.2 [46] => GeedoProductSearch [47] => SemrushBot [48] => vkShare [49] => inkrich [50] => Discordbot/2.0 [51] => IbouBot/1.0 [52] => trafilatura/1.6.3 [53] => AnsehnBot/1.0 [54] => WP-URLDetails/6.8.3 [55] => HubSpot Crawler [56] => ShapBot/0.1.0 [57] => udu/1.6.5 [58] => aiohttp/3.13.1 [59] => l9scan/2.0 [60] => Trident/5.0 [61] => SmartBotCrawler/1.0 [62] => ) The user agent is not in the allowed list.Array ( [0] => pingbot/2.0 [1] => Googlebot/2.1 [2] => ChatGPT-User/1.0 [3] => PerplexityBot/1.0 [4] => OAI-SearchBot/1.0 [5] => GPTBot/1.2 [6] => Perplexity-User/1.0 [7] => YandexBot/3.0 [8] => YandexFavicons/1.0 [9] => AdsBot-Google-Mobile [10] => AdsBot-Google [11] => Gemini-Deep-Research [12] => DuckAssistBot/1.1 [13] => DuckDuckBot/1.1 [14] => GoogleOther [15] => YandexRenderResourcesBot/1.0 [16] => YandexImages/3.0 [17] => DuckAssistBot/1.2 [18] => Baiduspider/2.0 [19] => Baiduspider-render/2.0 [20] => bingbot/2.0 [21] => YandexUserproxy [22] => Pingdom.com_bot_version_1.4_ [23] => GPTBot/1.3 [24] => PingdomPageSpeed/1.0 [25] => YandexMobileBot/3.0 [26] => OAI-SearchBot/1.3 [27] => ClaudeBot/1.0 [28] => OAI-SearchBot/1.3 [29] => ) The user agent is an allowed/known agent.
HbA1c Testing Market Size & Growth Forecast 2026–2035, By Segments (End-use, Technology, Type of Device), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Base Year Value (2025)
USD 2.66 Billion
CAGR (2026-2035)
9.2%
Forecast Year Value (2035)
USD 6.41 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035
HbA1c Testing Market Intelligence Snapshot:
-
Regional Market Dynamics:
- North America held a 45.75% market share in 2025, supported by routine diabetes screening, established laboratory infrastructure, and consistent integration of HbA1c testing into long-term disease management.
- Asia Pacific is projected to expand at a 10.4% CAGR as diabetes testing demand rises, healthcare access improves, and more patients enter routine monitoring and early detection programs.
-
Segment Momentum:
- Hospitals & Clinics held a 43.86% share in 2025 because they manage high testing volumes for diabetes diagnosis, monitoring, and treatment within established clinical care pathways.
- High-Performance Liquid Chromatography is the fastest-growing technology as healthcare providers increasingly prioritize reliable analytical performance for ongoing diabetes management.
-
Market Expansion Drivers:
- Increasing global diabetes prevalence driving demand for routine HbA1c testing.
- Adoption of point-of-care HbA1c devices improving clinical workflow efficiency.
- Rising obesity and aging populations increasing long-term glycemic monitoring needs.
-
Leading Market Participants:
Major companies in the HbA1c testing market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (United States), Tosoh Corporation (Japan), ARKRAY, Inc. (Japan), Trinity Biotech plc (Ireland), Danaher Corporation (United States), Sekisui Medical Co., Ltd. (Japan), Menarini Diagnostics S.r.l. (Italy).
Global Market Forecast Snapshot:
-
Market Outlook:
- 2025 Market Size: USD 2.66 Billion
- 2026 Market Size: USD 15.2 billion
- Projected Market Size: USD 6.41 Billion by 2035
- Growth Forecasts: 9.2% CAGR (2026-2035)
-
Regional and Segment Outlook:
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Hospitals & Clinics (End-use) | Immunoassays (Technology) | Laboratory-based Testing Devices (Type of Device)
- Emerging Opportunity Segment: Homecare Settings (End-use) | High-Performance Liquid Chromatography (Technology) | Point-of-care (POC)Testing Devices (Type of Device)
Market Growth Drivers and Industry Trends
Increasing global diabetes prevalence driving demand for routine HbA1c testingAs diabetes diagnoses expand across both developed and emerging healthcare systems, routine monitoring becomes a recurring clinical requirement rather than a one-time diagnostic event, directly reinforcing market demand for the HbA1c testing market. HbA1c testing is embedded in long-term disease management because clinicians rely on it to assess average glycemic control over time, adjust treatment plans, and track adherence between visits. This creates steady testing volumes through primary care, endocrinology, hospital outpatient services, and diagnostic laboratories, while payer and provider focus on preventing complications supports more regular test utilization and broader market penetration.
Adoption of point-of-care HbA1c devices improving clinical workflow efficiency
Point-of-care adoption is driving market development in the HbA1c testing market by shifting testing closer to the patient encounter and reducing the delays associated with centralized lab processing. When clinicians receive HbA1c results during the same visit, treatment adjustments, counseling, and follow-up decisions can happen immediately, which improves workflow efficiency and makes testing more actionable in routine diabetes care. This practical advantage is influencing market adoption among physician offices, diabetes clinics, and decentralized care settings where faster turnaround supports higher testing frequency and encourages procurement of compact analyzers and consumables.
Rising obesity and aging populations increasing long-term glycemic monitoring needs
Rising obesity rates and aging populations are contributing to market size growth in the HbA1c testing market by expanding the pool of individuals at elevated risk of impaired glucose regulation, type 2 diabetes, and related metabolic conditions that require ongoing surveillance. In practice, these populations generate sustained demand not only for diagnosis support but for repeated monitoring as comorbidities, medication changes, and progression risks make glycemic control more clinically complex over time. This dynamic is supporting market expansion through greater use of HbA1c testing in chronic care pathways, especially where healthcare providers are prioritizing early intervention and long-term management over episodic assessment.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing global diabetes prevalence driving demand for routine HbA1c testing | 2.20% | High | North America, Asia Pacific | High | Near Term |
| Adoption of point-of-care HbA1c devices improving clinical workflow efficiency | 2.00% | High | North America, Europe | High | Near Term |
| Rising obesity and aging populations increasing long-term glycemic monitoring needs | 1.60% | Moderate | Asia Pacific, Europe | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!
Regional Demand Dynamics
Largest Region
North America
45.75% Market Share in 2025
North America held the leading position in 2025, accounting for a 45.75% share of the HbA1c testing market. This regional dominance is underpinned by broad clinical use of HbA1c testing in diabetes diagnosis and long-term glucose monitoring, backed by established laboratory infrastructure and routine screening practices across care settings. Market activity is reinforced by the region’s ability to integrate testing consistently into hospital laboratories, diagnostic centers, and physician-led disease management workflows, which keeps testing volumes high in everyday clinical practice.
Asia Pacific is projected to expand at a 10.4% CAGR over the forecast period, with growth in the HbA1c testing market being propelled by rising diabetes testing needs and wider adoption of diagnostic services across healthcare systems. Demand is accelerating as more patients enter formal monitoring pathways and access to testing improves beyond major urban centers, increasing the practical use of HbA1c assays in both ongoing disease management and earlier detection settings.
| Regional Market Attractiveness & Strategic Fit Matrix | |||||
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub | Advanced | Developing | Advanced | Developing | Nascent |
| Cost-Sensitive Region | Low | Medium | Low | High | High |
| Regulatory Environment | Supportive | Neutral | Supportive | Neutral | Neutral |
| Demand Drivers | Strong | Strong | Strong | Moderate | Moderate |
| Development Stage | Developed | Developing | Developed | Emerging | Emerging |
| Adoption Rate | High | Medium | High | Low | Low |
| New Entrants / Startups | Dense | Moderate | Dense | Sparse | Sparse |
| Macro Indicators | Strong | Strong | Strong | Stable | Weak |
Key Country Insights
The U.S. continues to expand HbA1c testing across hospitals, diagnostic laboratories, and community care settings to improve diabetes management. Providers are prioritizing accessible and rapid testing solutions that support long-term patient monitoring and preventive care strategies.
Japan is strengthening the use of HbA1c testing to address the growing burden of age-related diabetes and metabolic disorders. Healthcare providers are integrating regular testing into preventive care and long-term disease management frameworks.
South Korea is increasing adoption of HbA1c testing in outpatient and community settings to improve early diabetes detection and monitoring. The market favors convenient diagnostic solutions that support efficient chronic disease management programs.
Germany is emphasizing HbA1c testing as a core component of structured diabetes care and disease monitoring programs. Demand is driven by the need for reliable testing platforms that support consistent treatment evaluation and patient management.
France is encouraging wider use of HbA1c testing to strengthen preventive strategies and improve management of patients at risk of diabetes complications. Laboratories are focusing on accurate and efficient testing services that support routine monitoring.
Italy is integrating HbA1c testing more deeply into chronic disease management pathways as diabetes prevalence places greater demand on healthcare services. Providers are prioritizing dependable testing technologies that facilitate regular patient assessment and treatment adjustment.
Segment Leadership and Growth Trends
Hospitals & Clinics accounted for a 43.86% share of the HbA1c testing market in 2025, reflecting their central role in routine diabetes diagnosis, treatment monitoring, and follow-up testing. This segment maintains leadership because hospitals and clinics handle a high volume of patients who require standardized testing within established care pathways, where HbA1c results are closely tied to physician evaluation and treatment decisions. Their access to integrated diagnostic infrastructure and regular patient visits also helps sustain consistent test demand across the HbA1c testing market.
Homecare Settings are emerging as the fastest-growing segment in the HbA1c testing market as diabetes management increasingly shifts toward more convenient and patient-directed care models. Growth is being supported by the practical need for testing options that fit ongoing monitoring outside traditional clinical environments, especially for patients seeking reduced dependence on facility-based visits. Compared with hospitals and clinics, homecare settings are gaining momentum because they align more directly with the rising preference for accessible long-term disease management in everyday settings.
Technology Segment Analysis: Immunoassays (Largest Segment) vs High-Performance Liquid Chromatography (Fastest-Growing Segment)
In 2025, Immunoassays held a 37.51% share of the HbA1c testing market, supported by their broad use in routine diagnostic workflows. Their dominant position is sustained by the practical fit of immunoassays in settings that require efficient, repeatable HbA1c testing as part of regular diabetes care, making them well suited for consistent day-to-day laboratory and clinical use. This operational convenience continues to reinforce their share across the HbA1c testing market.
High-Performance Liquid Chromatography is the fastest-growing technology segment in the HbA1c testing market because demand is increasing for testing approaches that can support more refined analytical performance in diabetes assessment. Its momentum relative to alternative technologies comes from its stronger alignment with settings where result quality and method reliability are key to clinical confidence. As care providers place greater emphasis on dependable measurement in ongoing diabetes management, High-Performance Liquid Chromatography is seeing faster adoption.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| End-use | Hospitals & Clinics, Diagnostic Laboratories, Homecare Settings | Hospitals & Clinics | Homecare Settings |
| Technology | Immunoassays, Chromatography, Enzymatic Assays, Boronate Affinity Chromatography, High-Performance Liquid Chromatography, Others | Immunoassays | High-Performance Liquid Chromatography |
| Type of Device | Laboratory-based Testing Devices, Point-of-care (POC)Testing Devices | Laboratory-based Testing Devices | Point-of-care (POC)Testing Devices |
Read our Research ApproachCompetitive Landscape and Market Positioning
Company Profile
Business Overview Financial Highlights Product Landscape SWOT Analysis Recent Developments Company Heat Map Analysis
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Siemens Healthineers AG (Germany)
4. Bio-Rad Laboratories Inc. (United States)
5. Tosoh Corporation (Japan)
6. ARKRAY Inc. (Japan)
7. Trinity Biotech plc (Ireland)
8. Danaher Corporation (United States)
9. Sekisui Medical Co. Ltd. (Japan)
10. Menarini Diagnostics S.r.l. (Italy)
Increasing emphasis on diabetes management is accelerating innovation in the HbA1c testing market, with manufacturers introducing automated analyzers, point-of-care diagnostic systems, and high-accuracy testing technologies that improve patient monitoring and clinical workflow efficiency.
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Orange Biomed | Mar-25 | Orange Biomed introduced an at-home HbA1c testing solution designed to enable accurate diabetes monitoring from a small blood sample. The system leverages microfluidics and single-cell analysis to improve accessibility and decentralize glycemic control tracking, supporting the shift toward patient-centric diagnostic models and expanding home-based chronic disease management capabilities. |
| FIND / Abbott / i-SENS / Siemens Healthineers | Apr-23 | FIND partnered with Abbott, i-SENS Inc, and Siemens Healthineers to provide discounted point-of-care HbA1c test kits for low- and middle-income countries. The initiative aims to improve diabetes diagnosis and monitoring accessibility in underserved regions by expanding availability of affordable diagnostic tools across decentralized healthcare settings. |
| LumiraDx | Nov-22 | LumiraDx expanded the commercial reach of its HbA1c testing platform, enabling broader adoption across multiple care settings. The system delivers rapid results for diabetes screening and monitoring, supporting improved clinical decision-making and strengthening point-of-care diagnostic capabilities in decentralized healthcare environments. |
| Labcorp | May-22 | Labcorp introduced an at-home diabetes risk testing kit using a home collection device developed by Weavr Health. The solution enhances accessibility to diagnostic services by enabling remote sample collection and supports the broader shift toward home-based screening and preventive care in diabetes management. |
Frequently Asked Questions
What is the current revenue of the HbA1c testing market?
The market valuation of the HbA1c testing is USD 2.87 billion in 2026.
What is the forecasted size of the HbA1c testing industry?
HbA1c Testing Market size is projected to grow steadily from USD 2.66 billion in 2025 to USD 6.41 billion by 2035 demonstrating a CAGR exceeding 9.2% through the forecast period (2026-2035).
How is point-of-care HbA1c testing changing procurement and clinical workflow priorities?
Point-of-care testing enables clinicians to receive results during patient visits, allowing immediate treatment decisions and improving workflow efficiency. This supports procurement of compact analyzers and consumables across physician offices and decentralized care settings.
What factors are sustaining long-term demand for HbA1c testing across healthcare systems?
Increasing diabetes prevalence, along with rising obesity and aging populations, is expanding the need for ongoing glycemic monitoring. This reinforces recurring testing across chronic disease management pathways and supports broader adoption in routine clinical practice.
Why do hospitals and clinics lead the HbA1c testing market?
Hospitals & Clinics held a 43.86% share in 2025 because they manage high testing volumes for diabetes diagnosis, monitoring, and treatment within established clinical care pathways.
Which technology segment is growing the fastest in the HbA1c testing market?
High-Performance Liquid Chromatography is the fastest-growing technology as healthcare providers increasingly prioritize reliable analytical performance for ongoing diabetes management.
Why does North America dominate the HbA1c testing market?
North America held a 45.75% market share in 2025, supported by routine diabetes screening, established laboratory infrastructure, and consistent integration of HbA1c testing into long-term disease management.
What is fueling HbA1c testing market growth in Asia Pacific?
Asia Pacific is projected to expand at a 10.4% CAGR as diabetes testing demand rises, healthcare access improves, and more patients enter routine monitoring and early detection programs.
Which companies are driving growth in the HbA1c testing landscape?
Major companies in the HbA1c testing market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (United States), Tosoh Corporation (Japan), ARKRAY, Inc. (Japan), Trinity Biotech plc (Ireland), Danaher Corporation (United States), Sekisui Medical Co., Ltd. (Japan), Menarini Diagnostics S.r.l. (Italy).
Our Clients
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
